Salmon calcitonin reduces vertebral bone loss in glucocorticoid-treated beagles.


Journal Article

Glucocorticoids induce bone loss by increasing bone resorption and decreasing bone formation. In this study we have investigated the potential of salmon calcitonin to attenuate glucocorticoid-induced bone loss in a dog model. Male beagles were divided into three groups: 1) untreated controls, 2) prednisone-treated dogs (1 orally), and 3) prednisone-calcitonin-treated dogs (1.5 calcitonin subcutaneously and 1 prednisone orally). Assessment of bone mass by dual energy X-ray absorptiometry demonstrated that bone density remained stable in controls throughout 48 wk. Prednisone-treated dogs lost 13.2% of their initial bone mass by 48 wk. Concomitant calcitonin treatment attenuated prednisone-induced bone loss to only 3.2% at 48 wk. Bone histomorphometry of the spine showed reduced trabecular bone volume in prednisone-treated dogs, whereas control and prednisone-calcitonin-treated animals maintained normal trabecular bone volume. Both prednisone- and prednisone-calcitonin-treated dogs acquired a defect in osteoblastic function as evidenced by a reduction in mean wall thickness and trabecular thickness. Thus calcitonin attenuates the early bone loss induced by glucocorticoids. However, calcitonin failed to prevent glucocorticoid-induced osteoblast dysfunction.

Full Text

Duke Authors

Cited Authors

  • Lyles, KW; Jackson, TW; Nesbitt, T; Quarles, LD

Published Date

  • June 1, 1993

Published In

Volume / Issue

  • 264 / 6 Pt 1

Start / End Page

  • E938 - E942

PubMed ID

  • 8333518

Pubmed Central ID

  • 8333518

International Standard Serial Number (ISSN)

  • 0002-9513

Digital Object Identifier (DOI)

  • 10.1152/ajpendo.1993.264.6.E938


  • eng

Conference Location

  • United States